Resumen de Post-docetaxel treatments for metastatic castrationresistant prostate cancer: A spanish single center experience

Laura Delgado Téllez, Amaia Egües Lugea, Carmen Perezagua Marín, Mª Carmen Herrero Domínguez-Berrueta, María Angeles Campos Fernández de Sevilla, Federico Tutau Gómez

• New treatments have been available for metastatic Castration-Resistant Prostate Cancer (mCRPC).

  Purpose: To describe effectiveness and safety of different new treatments in mCRPC patients treated with docetaxel.

  Method: A retrospective observational study in 10 mCRPC patients. The Progression-Free Survival (PFS), Overall Survival (OS) and safety of abiraterone and cabazitaxel has been measured.

  Results: Abiraterone has been well tolerated with greater PFS and PSA response but less OS than pivotal study. Cabazitaxel had better PFS but less OS than pivotal study with a high incidence of asthenia.

  Conclusions: Abiraterone has been the second line most used followed by cabazitaxel, but not all patients have been candidates for three lines. A better knowledge of the sequencing current therapies will allow to increase effectiveness in these patients